Gilead Bets Billions on Diversification, But Key UC Asset Emvistegrast Remains a Black Box

Gilead Advances Inflammation, Oncology Pipeline Amid Diversification Push

Gilead Sciences is actively pursuing diversification beyond its dominant HIV franchise, with a strategic focus on inflammation and oncology. The company's second-quarter 2026 earnings report highlighted this shift, with CEO Daniel O'Day emphasizing the objective to build new revenue streams. Key upcoming catalysts in the latter half of 2026 include data readouts for emvistegrast in Phase 2 for ulcerative colitis and edecesertib in Phase 2 for cutaneous lupus erythematosus. Additionally, potential FDA approval for the CAR T therapy anito-cel in relapsed or refractory multiple myeloma is anticipated by December 2026. Financially, Gilead reported Q2 revenues of $7.8 billion, a 10% year-on-year increase, with HIV contributing $5.7 billion. The company also made significant acquisitions, including Arcellx for $7.8 billion, Tubulis GmbH for up to $5 billion, and Ouro Medicines for $2.1 billion, further bolstering its non-virology pipeline. PrEP sales, including Yeztugo and Descovy, collectively surpassed $1 billion for the first time.

• Gilead is intensifying its efforts to diversify its business beyond its strong HIV franchise, responding to investor pressure and a clear corporate objective. This strategy involves a significant pivot towards inflammation and oncology, with a packed schedule of upcoming catalysts in the second half of 2026. The company is leveraging both internal drug development and strategic acquisitions to build a robust pipeline and new commercial revenue streams outside of virology.
• The latter half of 2026 is critical for Gilead's pipeline, featuring several anticipated readouts. These include Phase 2 data for the integrin inhibitor emvistegrast in the SWIFT trial for ulcerative colitis and for the kinase blocker edecesertib in the COSMIC trial for cutaneous lupus erythematosus. In oncology, the CAR T therapy anito-cel, acquired through Arcellx, is nearing a potential FDA approval decision by December 2026 for relapsed or refractory multiple myeloma as a fourth-line option.
• Gilead reported strong financial results for Q2 2026, with total revenues reaching $7.8 billion, marking a 10% increase year-on-year. The HIV franchise remained a cornerstone, contributing $5.7 billion, up 12% from the previous year, driven by consistent performers like Biktarvy ($3.8 billion). Notably, the company's PrEP sales, including Yeztugo and Descovy, collectively exceeded $1 billion for the first time, with Yeztugo demonstrating a high persistency rate of over 70%.

Addressing the Persistent Challenges in Ulcerative Colitis Treatment

Despite significant advances in ulcerative colitis (UC) management, a substantial proportion of patients continue to face suboptimal outcomes, reflecting persistent gaps between available therapies and unmet clinical needs. These limitations span efficacy, safety, accessibility, and the pace of therapeutic innovation, underscoring the need for continued research and refinement of treatment paradigms.

• Limited and unpredictable efficacy: Many patients with moderate-to-severe UC experience treatment failure, primary non-response, or loss of response over time, and a therapeutic ceiling persists even with biologic agents. Long-term remission remains difficult to achieve, and surgery is sometimes ultimately required due to uncontrolled disease activity or complications.

• Growing anti-TNF-experienced population: An increasing proportion of patients have already failed anti-TNF therapy, intensifying the need for new agents with alternative mechanisms of action beyond this well-established class.

• Safety and tolerability concerns: Conventional therapies are frequently associated with substantial adverse effects, while biologics carry risks of immunogenicity and loss of response over time. Small-molecule agents such as JAK inhibitors offer oral, rapid-onset alternatives but raise systemic safety concerns that require careful monitoring.

• Standard induction regimens may be insufficient: Fixed 8-week induction courses with agents such as upadacitinib may not achieve adequate response in all patients with moderate-to-severe active UC. Emerging evidence supports extended induction strategies—upadacitinib (12–24 weeks) and tofacitinib beyond 8 weeks—demonstrating improved clinical response and mucosal healing without compromising safety, pointing toward a response-guided rather than fixed-duration induction paradigm.

• Cost and accessibility barriers: Newer, more effective biologic and small-molecule therapies remain expensive and are not readily accessible in many countries, particularly low- and middle-income regions. This highlights the urgent need for biosimilars, international policy support, and strategies to ensure equitable global access.

• Historical underinvestment in UC-specific research: Compared with Crohn's disease, UC received comparatively less scientific attention for many years, as it was not historically regarded as a progressive disease capable of inducing irreversible bowel damage—resulting in slower development of dedicated therapeutic options.

• Need for personalized and combination approaches: Given the heterogeneity of treatment response, future strategies should focus on mitigating drug resistance, reducing costs, and integrating personalized medicine. Emerging dual-targeted therapy approaches—combining two biologic agents sequentially or concurrently—are being explored to break through the current therapeutic ceiling, with early controlled evidence (e.g., the VEGA trial) suggesting superior disease control versus monotherapy without added safety risk.

Emvistegrast: An Integrin Inhibitor in the UC Pipeline

Emvistegrast is entering a competitive landscape of gut-selective therapies targeting the α4β7 integrin pathway. This mechanism, successfully commercialized with the approval of vedolizumab for ulcerative colitis and Crohn's disease, has a robust pipeline of other investigational agents. Several other monoclonal antibodies targeting this interaction have been evaluated in clinical trials, demonstrating continued interest in this therapeutic strategy for inflammatory bowel disease.

Navigating the Evolving Ulcerative Colitis Treatment Landscape

Over the last five years, the ulcerative colitis (UC) therapeutic armamentarium has significantly expanded beyond established biologics with the introduction of new drug classes, including Janus kinase (JAK) inhibitors, sphingosine-1-phosphate receptor (S1PR) modulators, and interleukin (IL)-23 inhibitors. Agents such as the S1PR modulator ozanimod and the IL-23 inhibitor guselkumab have demonstrated significant efficacy over placebo in inducing clinical remission, endoscopic improvement, and mucosal healing. This expansion has coincided with a paradigm shift toward earlier and broader use of advanced therapies, with biologics being initiated on average 762 days sooner relative to diagnosis in 2018 compared to 2008. Treatment goals have also become more ambitious, with emerging concepts like "disease clearance"—a composite of clinical, endoscopic, and histological remission—being proposed as the new target to improve long-term outcomes, in line with STRIDE-II guideline recommendations.

As the number of therapeutic options grows, comparative effectiveness and safety data are becoming crucial for treatment sequencing. Network meta-analyses suggest that upadacitinib may be the most effective agent for inducing clinical remission, while ustekinumab ranks favorably for its safety profile. Distinct safety signals have been identified across classes, with IL-23 antagonists appearing to be the safest, while S1PR modulators and JAK inhibitors are associated with low but notable rates of infectious and cardiovascular events. In biologic-naive patients, adalimumab has been associated with slightly lower remission rates compared to infliximab or vedolizumab, and combination therapy with a thiopurine has shown superior remission odds over biologic monotherapy. While advanced therapies demonstrate similar efficacy in older (≥60 years) and younger adults, the risk of serious infection is significantly higher in the older population.

Despite these advances, real-world data reveals significant challenges in achieving durable disease control. Treatment persistence for advanced therapies remains low, with less than 40% of patients remaining on treatment at three years, and frequent dose escalations or therapy switches are common. One real-world study found that nearly half of patients had an inadequate response within the first year. This highlights the challenge of a "difficult-to-treat" population, representing about 17% of patients who cycle through multiple therapies. In contrast, recent population-based cohort data (IBSEN III) shows encouraging 1-year outcomes with a low colectomy rate (0.9%) and high steroid-free remission (76.6%), indicating that while many patients respond well to modern strategies, a substantial unmet need persists. The scarcity of head-to-head trials and lack of validated predictive biomarkers remain critical hurdles to personalizing therapy and breaking the current therapeutic ceiling.